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	 Is	aspirin	effective	for	primary	
prevention	of	colon	cancer?	
it’s unclear, due to conflict-
ing evidence.	 Aspirin	 probably	
shouldn’t	 be	 used	 for	 routine	 prevention	
because	 of	 its	 potential	 risks	 (strength	 of	
recommendation	 [SOR]:	B,	 systematic	 re-
view	 of	 inconsistent	 evidence).	 However,	
aspirin	is	likely	to	be	effective	for	secondary	
prevention	 of	 colorectal	 adenomas	 (SOR:	
A,	systematic	review).	
EvidEncE-basEd answEr
A
Evidence summary
A	 systematic	 review	 conducted	 for	 the	 US	
Preventive	Services	Task	Force	(USPSTF)	ad-
dressed	 the	 use	 of	 aspirin	 for	 primary	 pre-
vention	 of	 colorectal	 carcinomas	 (CRC)	 and	
colorectal	adenomas	(CRA).	
Pooled	 data	 from	 2	 randomized-	
controlled	trials	(RCTs)	with	a	total	of	61,947	
patients	showed	no	decrease	in	CRC	incidence	
(relative	risk	[RR]=1.02;	95%	confidence	inter-
val	 [CI],	 0.84-1.25)	 with	 regular	 aspirin	 use	
(325	mg	every	other	day	for	5	years	or	100	mg	
every	other	day	for	10	years).	Six	cohort	stud-
ies	that	followed	a	total	of	231,252	patients	did	
report	a	decrease	in	CRC	incidence	over	4	to	
10	years	(RR=0.78;	95%	CI,	0.63-0.97).1
In	a	pooled	analysis	evaluating	2	primary	
prevention	RCTs	(the	British	Doctors	Aspirin	
Trial	and	UK-TIA	Aspirin	Trial,	total	N=7588),	
aspirin	was	found	to	reduce	the	incidence	of	
colorectal	 cancer	 (hazard	 ratio	 [HR]=0.74;	
95%	 CI,	 0.56-0.97;	 P=.02	 overall;	 for	 aspirin	
given	 for	5	years	or	 longer,	HR=0.63;	95%	CI,	
0.47-0.85;	P=.002).	The	 effect	 was	 significant	
only	 at	 10	 to	 14	 years	 of	 follow-up	 (0	 to	 9	
years:	HR=0.92,	95%	CI,	0.56-1.49,	P=.73;	5	to	
9	years:	HR=1.08,	95%	CI,	0.55-2.14,	P=.83;	10	
to	14	years:	HR=0.51,	95%	CI,	0.29-0.90,	P=.02;	
15	 to	 19	 years:	 HR=0.70,	 95%	 CI,	 0.43-1.14,	
P=.15;	≥20	years:	HR=0.90,	95%	CI,	0.42-1.95,	
P=.79).2	
Adverse effects, including stroke,  
are dose-dependent
The	 USPSTF	 review	 also	 summarized	 the	
harms	 associated	 with	 aspirin	 use.	 When	
aspirin	 was	 given	 for	 secondary	 preven-
tion	of	stroke,	 the	risk	of	hemorrhagic	stroke	
was	 dose-dependent,	 varying	 from	 0.3%	 to	
1.1%	 (100	 mg/d:	 0.3%,	 95%	 CI,	 0.2%-0.4%;	
100-325	 mg/d:	 0.3%,	 95%	 CI,	 0.2%-0.3%;	
325	mg/d:	1.1%,	95%	CI,	0.7%-1.5%).	
Aspirin	 also	 was	 associated	 with	 an	 in-
creased	 risk	 of	 gastrointestinal	 (GI)	 symp-
toms	 (odds	 ratio	 [OR]=1.7;	 95%	 CI,	 1.5-1.8),	
GI	bleeding	(RR=1.6-2.5),	and	hospitalization	
for	GI	bleeding	(OR=1.9;	95%	CI,	1.1-3.1).	The	
risks	of	GI	bleeding	or	perforation	were	dose-
dependent.1	
Low-dose aspirin promotes  
secondary prevention of adenomas
In	a	Cochrane	review	evaluating	the	effects	of	
aspirin	on	CRA,	pooled	data	from	3	RCTs	with	
a	total	of	1839	subjects	(1322	with	a	history	of	
CRA	and	517	with	a	history	of	CRC)	 showed	
that	aspirin	in	a	daily	dose	of	81	mg	is	effective	
for	secondary	prevention	of	sporadic	CRA	over	
a	1-	to	3-year	follow-up	period	(RR=0.77;	95%	
CI,	 0.61-0.96;	 number	needed	 to	 treat=12.5).	
The	outcome	measured	 in	 these	 3	 trials	was	
an	intermediate	clinical	finding,	CRA,	and	not	
the	more	relevant	end	point	of	CRC.3	
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Recommendations 
The	USPSTF	recommends	against	routine	use	
of	aspirin	and	nonsteroidal	anti-inflammatory	
drugs	to	prevent	colorectal	cancer	in	people	at	
average	risk	(grade	D	recommendation:	inef-
fective	or	harm	outweighs	benefits).4	
The	 American	 Gastroenterological	 Asso-
ciation	 (AGA)	 doesn’t	 recommend	 aspirin	 for	
primary	CRC	prevention,	 but	 acknowledges	 a	
possible	role	 in	secondary	prevention.	Aspirin	
should	 be	 considered	 for	 patients	with	 a	 per-
sonal	history	of	CRC,	advanced	CRA,	or	a	strong	
family	history	but	no	history	of	peptic	ulcer	dis-
ease	or	hemorrhagic	stroke.	The	AGA	notes	that	
1	in	100	people	taking	aspirin	for	2	years	will	de-
velop	significant	GI	bleeding.5		 														JFP
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